Positive new five-year follow-up of the pivotal Phase III POLARIX study evaluating Polivy (polatuzumab vedotin) in combination with MabThera/Rituxan (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP) in people with untreated diffuse large B-cell lymphoma (DLBCL) were released on Sunday by Swiss pharma giant Roche (ROG: SIX) at the American Society of Hematology (ASH) Annual Meeting in San Diego, USA.
“POLARIX was the first trial to elevate treatment standards for frontline diffuse large B-cell lymphoma in 20 years and we are additionally encouraged by the five-year follow-up results,” said Dr Levi Garraway, Roche’s chief medical officer and head of global product development. “More than 38,000 people worldwide have been treated with Polivy in combination with R-CHP and these data continue to underscore its potential to improve outcomes for people diagnosed with this aggressive lymphoma,” he noted.
An expansion into front-line DLBCL could mean $2.1 billion in additional peak sales for Polivy, Jefferies analyst Peter Welford said in a September note to clients. The Roche antibody-drug conjugate now looks more likely to hit that goal, given its benefit on the progression-free survival marker came in at the higher end of physicians’ expectations.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze